From: Heterogeneity in malaria exposure and vaccine response: implications for the interpretation of vaccine efficacy trials
Group
Proportion infected I(T)
Person years at risk PYAR
Control
1 - e-ΛT
Vaccine
1 - e-(1 - VE)ΛT